durvalumab + lenalidomide + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone

This is a **combination regimen** consisting of seven drugs: - Durvalumab: a monoclonal antibody targeting the immune checkpoint programmed cell death ligand 1 (PD-L1), enhancing antitumor immune responses. - Lenalidomide: an immunomodulatory agent with antineoplastic, antiangiogenic, and pro-erythropoietic properties, affecting both tumor cells and the tumor microenvironment. - Rituximab: a monoclonal antibody targeting the CD20 antigen on B lymphocytes, resulting in antibody-dependent cellular cytotoxicity and complement-mediated lysis. - Cyclophosphamide: a small molecule alkylating agent that crosslinks DNA, leading to apoptosis in rapidly dividing cells. - Doxorubicin: an anthracycline antibiotic and topoisomerase II inhibitor that intercalates DNA, inhibiting replication and transcription. - Vincristine: a vinca alkaloid inhibiting microtubule formation, blocking mitosis. - Prednisone: a synthetic glucocorticoid steroid with lympholytic, anti-inflammatory, and immunosuppressive activity. This multi-drug regimen targets cancer cells through **immune modulation**, **B-cell depletion**, **DNA damage**, **mitotic inhibition**, and **steroid-induced cytotoxicity**, and would be considered in relapsed or refractory hematological malignancies, or in experimental protocols.